Bioactivity was evaluated using a modified Boyden chamber assay of the chemotactic migration of HUVEC.(12) Finally, we examined the anti-tumor angiogenesis properties of selected ChM-I mimetic peptides in a human chondrosarcoma xenograft model in vivo. The gene discussed is CNMD; the disease is chondrosarcoma.